Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + FOLFIRI in 2nd Line Advanced Colorectal Cancer
NCT04810585Phase 4Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2020
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in colorectal cancer (CRC), sponsored by Yonsei University. Primary endpoint: Progression-Free Survival up to 5 years. Status: unknown.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04810585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810585.